NEW YORK, Dec. 17, 2012 /PRNewswire/ — Reportlinker.com announces that a new market research report is available in its catalogue: North America In Vitro Diagnostics Market Outlook to 2018- Clinical …
NEW YORK, Dec. 17, 2012 /PRNewswire/ — Reportlinker.com announces that a new market research report is available in its catalogue: Europe Anesthesia and Respiratory Devices Market Outlook to 2018 – Respiratory …
An unprecedented method of turning a sliver of skin into a protein manufacturing plant has been advancing in the process of clinical testing for entry into the hundred billion dollar plus protein therapy …
Medgenics` (NYSEAMEX: MDGN) INFRADURE(TM) provides sustained production and delivery of interferon-alpha for the treatment of hepatitis. INFRADURE(TM) is a kind of miniature pump that is impacted into …
By Sharon di Stefano, Contributor Medgenics` (NYSEAMEX: MDGN) and (AIM: MEDU) (AIM: MEDG) INFRADURE(TM) provides sustained production and delivery of interferon-alpha for the treatment of hepatitis. INFRADURE(TM) …
Astellas Pharma Inc. and Ambit Biosciences Corporation today announced the results from a completed phase II study with the investigational FLT3 inhibitor,
Jakavi demonstrated rapid reductions in spleen size and improved quality of life in Phase III studies, with results sustained over two years COMFORT-II follow-up results show Jakavi may improve overall …
ATLANTA, Dec. 10, 2012 /PRNewswire/ — Astellas Pharma Inc. (Tokyo: 4503, Astellas) and Ambit Biosciences Corporation announced today that the results from a completed Phase 2 study with the investigational …
NEW YORK, Dec. 10, 2012 /PRNewswire/ — Reportlinker.com announces that a new market research report is available in its catalogue: Global Kidney Dialysis Equipment And Supplies Industry http://www.reportlinker.com/p090652/Global-Kidney-Dialysis-Equipm…
NORTHBROOK, Ill., Dec. 4, 2012 /PRNewswire/ — Astellas Pharma US, Inc. ("Astellas"), a U.S. subsidiary of Tokyo-based Astellas Pharma Inc. (Tokyo: 4503), announced today that the U.S. Food and …